Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16014770 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2KMOPLA2G7CYP3A4GAA | |
| SCHEMBL1531326 | 0.81 | PDE10A (0.47) | SMN1; SMN2KMOGAATSHRALDH1A1 | |
| SCHEMBL18755105 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2KMOCYP3A4GAATSHR | |
| SCHEMBL4001656 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2KMOALDH1A1NPSR1HSD11B1 | |
| SCHEMBL30147353 | 0.76 | HSD11B1 (0.61) | SMN1; SMN2KMOALDH1A1P2RX7LMNA | |
| SCHEMBL13225992 | 0.76 | SMN1; SMN2 (0.36) | SMN1; SMN2KMOALDH1A1NPSR1MAPT | |
| SCHEMBL14531124 | 0.75 | KMO (0.44) | SMN1; SMN2KMOGAAALDH1A1NPSR1 | |
| SCHEMBL926356 | 0.75 | LMNA (0.56) | SMN1; SMN2KMOALDH1A1LMNAMAPT | |
| SCHEMBL17359685 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2KMOGAATSHRALDH1A1 | |
| SCHEMBL3375138 | 0.72 | SMN1; SMN2 (0.52) | SMN1; SMN2KMOCYP3A4GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875609-B2 | 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis | GALAPAGOS SASU (FR) | 2011-01-25 | — | — | US | disclosed |
| US-7875609-B2 | 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis | GALAPAGOS SASU (FR) | 2011-01-25 | — | — | US | disclosed |
| US-7875609-B2 | 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis | GALAPAGOS SASU (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1965805-B1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2009-12-02 | — | — | EP | disclosed |
| EP-1965805-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | Proskelia SAS (FR) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | disclosed |
| WO-2007060026-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060026-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | UTS2R, CACNA1A, CACNA1E | SMN1; SMN2 3946/4885KMO 4449/4885PLA2G7 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.